Welcome to our dedicated page for Lensar news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on Lensar stock.
Lensar Inc (LNSR) delivers innovative femtosecond laser systems transforming refractive cataract surgery through proprietary augmented reality imaging. This comprehensive news hub provides investors and medical professionals with essential updates on the company’s technological advancements, financial performance, and market developments.
Access real-time announcements including quarterly earnings reports, product launch details, regulatory milestones, and strategic partnerships. Our curated collection ensures you stay informed about LNSR’s progress in commercializing its precision surgical platforms and expanding its global footprint in ophthalmic care.
Key updates cover FDA clearances, clinical study results, system installations, and executive leadership changes. All content is verified through primary sources to maintain accuracy and compliance with financial disclosure standards.
Bookmark this page for centralized access to Lensar’s official communications and third-party analyses. Monitor the company’s trajectory in advancing cataract surgery technology while maintaining awareness of industry trends affecting medical device innovation.
Alcon (NYSE: ALC) has announced a definitive merger agreement to acquire LENSAR (NASDAQ: LNSR) in a deal worth up to $430 million. The acquisition includes LENSAR's ALLY Robotic Cataract Laser Treatment System, Streamline® software, and legacy laser system. Alcon will pay $14.00 per share in cash (approximately $356 million), with an additional contingent value right of up to $2.75 per share based on achieving 614,000 procedures between 2026-2027.
The deal represents a premium of 24% to LENSAR's 30-day VWAP and 47% to its 90-day VWAP. The acquisition strengthens Alcon's femtosecond laser-assisted cataract surgery (FLACS) portfolio and aims to expand advanced laser technology globally. With over 5 million cataract procedures in the U.S. and 32 million globally, the transaction is expected to close in mid-to-late 2025, subject to regulatory and stockholder approval.
Alcon (SIX/NYSE: ALC) has announced a definitive merger agreement to acquire LENSAR (NASDAQ: LNSR), acquiring all outstanding shares at $14.00 per share in cash ($356 million), with an additional contingent value right of up to $2.75 per share based on procedure milestones, bringing potential total consideration to $430 million.
The acquisition includes LENSAR's ALLY Robotic Cataract Laser Treatment System, Streamline® software technology, and legacy laser system, strengthening Alcon's femtosecond laser-assisted cataract surgery (FLACS) portfolio. The deal offers a 24% premium to LENSAR's 30-day VWAP and 47% premium to 90-day VWAP.
With over 5 million cataract procedures in the US and 32 million globally, this acquisition aims to expand advanced femtosecond laser technology accessibility worldwide. The transaction is expected to close in mid-to-late 2025, subject to regulatory approval and LENSAR stockholder approval.
Alcon (SIX/NYSE: ALC) has entered into a definitive merger agreement to acquire LENSAR (NASDAQ: LNSR), strengthening its cataract equipment portfolio. The acquisition includes LENSAR's ALLY Robotic Cataract Laser System, Streamline software, and legacy laser system.
The deal values LENSAR at $14.00 per share in cash (approximately $356 million), with an additional contingent value right of up to $2.75 per share based on achieving 614,000 cumulative procedures between 2026-2027. The total potential consideration of $16.75 per share represents a 24% premium to LENSAR's 30-day VWAP and 47% to 90-day VWAP, potentially reaching $430 million.
The acquisition targets the growing cataract surgery market, with over 5 million procedures in the U.S. and 32 million globally. The transaction is expected to close in mid-to-late 2025, subject to regulatory approval and LENSAR stockholder approval.
LENSAR (NASDAQ: LNSR) has announced the granting of stock options to two newly-hired non-executive employees as employment inducements. The grants, approved by independent board members on March 3, 2025, allow the purchase of a total of 1,600 shares of common stock at $13.48 per share, matching the closing price on the grant date.
The options feature a vesting schedule where 25% vests after one year, followed by 36 monthly installments, contingent on continued employment. These 10-year term options were granted under LENSAR's 2024 Employment Inducement Incentive Award Plan and comply with Nasdaq Listing Rule 5635(c)(4).
LENSAR (NASDAQ: LNSR) reported strong Q4 and full-year 2024 results, with significant growth in ALLY Robotic Cataract Laser System placements and revenue. The company placed 31 ALLY systems in Q4, contributing to over 80 placements in 2024 - an 86% increase over 2023. Total installed systems reached approximately 385, up 26% from 2023.
Q4 2024 revenue increased 38% to $16.7 million, while full-year revenue grew 27% to $53.5 million. Recurring revenue exceeded $40 million for the year, up 23%. Worldwide procedure volumes grew 24% to nearly 170,000, with U.S. market share exceeding 20%. Despite positive operational metrics, the company reported a Q4 net loss of $18.7 million, primarily due to warrant liability changes from stock price appreciation.
For 2025, LENSAR expects revenue growth to accelerate beyond the 27% achieved in 2024, with Q1 2025 growth projected at 27% and further acceleration in subsequent quarters. The company anticipates achieving positive Adjusted EBITDA in 2025.
LENSAR (Nasdaq: LNSR), a global medical technology company specializing in robotic laser solutions for cataract treatment, has announced its schedule for releasing fourth quarter and full year 2024 financial results. The results will be released before market open on Thursday, February 27, 2025.
The company's management will host a conference call and webcast at 8:30 am ET on the same day to discuss financial results and recent corporate highlights. Participants must register in advance to join the telephone conference. A live webcast will be available in the Investor Relations section of LENSAR's website, with replay access available until March 20, 2025.
LENSAR (NASDAQ: LNSR) announced the granting of stock options to two newly-hired non-executive employees as employment inducements. The grants, approved by independent board members, total 875 shares with an exercise price of $10.65 per share, matching the closing price on February 3, 2025.
The options will vest 25% on the one-year anniversary of the grant date, followed by thirty-six monthly installments, contingent on continued employment. The options have a 10-year term and are governed by LENSAR's 2024 Employment Inducement Incentive Award Plan and stock option agreements.
LENSAR (NASDAQ: LNSR) has announced the granting of stock options to three newly-hired non-executive employees. The independent board members approved options to purchase a total of 1,650 shares of common stock, effective January 2, 2025. The options were granted as employment inducements under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $8.69 per share, matching the closing price on the grant date. The vesting schedule includes 25% of the total award after one year, followed by 36 monthly installments, contingent on continued employment. The options have a 10-year term and are governed by LENSAR's 2024 Employment Inducement Incentive Award Plan.
FAQ
What is the current stock price of Lensar (LNSR)?
What is the market cap of Lensar (LNSR)?
